December 1, 2020Open Access

Study of Tofacitinib in Refractory Dermatomyositis: An Open‐Label Pilot Study of Ten Patients

Key Points

Key points are not available for this paper at this time.

Abstract

This is the first prospective, open-label clinical trial of tofacitinib in DM that demonstrates strong clinical efficacy of a pan-JAK inhibitor, as measured by validated myositis response criteria. Future randomized controlled trials using JAK inhibitors should be considered for treating DM.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Paik et al. (Tue,) studied this question.

synapsesocial.com/papers/69daab723bc1ef72256848dc https://doi.org/https://doi.org/10.1002/art.41602

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Polymyositis and Dermatomyositis1975 · 5,100 citations
2Contribution of NKX2-3 Polymorphisms to Inflammatory Bowel Diseases: A Meta-Analysis of 35358 subjects2014 · 12 citations
3TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions2013 · 13,653 citations
4Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change2015 · 98 citations
5Identification of distinctive interferon gene signatures in different types of myositis2019 · 225 citations

Bookmark

View Full Paper